Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Open Access
- 1 June 2020
- Vol. 12 (6), 1448
- https://doi.org/10.3390/cancers12061448
Abstract
Src is the prototypal member of Src Family tyrosine Kinases (SFKs), a large non-receptor kinase class that controls multiple signaling pathways in animal cells. SFKs activation is necessary for the mitogenic signal from many growth factors, but also for the acquisition of migratory and invasive phenotype. Indeed, oncogenic activation of SFKs has been demonstrated to play an important role in solid cancers; promoting tumor growth and formation of distant metastases. Several drugs targeting SFKs have been developed and tested in preclinical models and many of them have successfully reached clinical use in hematologic cancers. Although in solid tumors SFKs inhibitors have consistently confirmed their ability in blocking cancer cell progression in several experimental models; their utilization in clinical trials has unveiled unexpected complications against an effective utilization in patients. In this review, we summarize basic molecular mechanisms involving SFKs in cancer spreading and metastasization; and discuss preclinical and clinical data highlighting the main challenges for their future application as therapeutic targets in solid cancer progressionThis publication has 178 references indexed in Scilit:
- Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumoursBritish Journal of Cancer, 2012
- Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanomaBritish Journal of Cancer, 2011
- Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast CancerClinical Breast Cancer, 2011
- Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate CancerUrology, 2011
- Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinomaCancer, 2010
- A phase 2 trial of dasatinib in advanced melanomaCancer, 2010
- Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor ProgressionJournal of Mammary Gland Biology and Neoplasia, 2010
- An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progressionNature Medicine, 2009
- N‐WASP and cortactin are involved in invadopodium‐dependent chemotaxis to EGF in breast tumor cellsCell Motility, 2009
- Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and FunctionCancer Cell, 2009